Algorithmiq, Quantum Circuits partnership uses quantum computing to streamline pharmaceutical molecular simulations
Algorithmiq, a company specializing in quantum algorithms for life sciences, has announced a partnership with Quantum Circuits to demonstrate faster, more accurate molecular simulation for drug discovery.
The partners are using Quantum Circuit’s full-stack Aqumen Seeker quantum computing system, which uses industry-first dual-rail qubits with built-in error correction.
Algorithmiq’s research includes detailed molecular simulations that predict important properties, such as enzyme pharmacokinetics, the study of how enzymes within the body affect the absorption, distribution, metabolism and excretion of a drug.
While the company has previously run its algorithms on classical computers, its drug discovery approach requires faster, complex calculations that cannot be achieved by traditional classical computers alone.
Aqumen Seeker is an 8-qubit quantum processor that follows a “correct first, then scale” approach. It enables Algorithmiq to design algorithms that reduce the impact of errors and bypass inefficient brute-force techniques that limit quantum computing’s commercial readiness.
“At Algorithmiq, we are demonstrating how quantum computing can transform drug discovery with practical, scalable solutions,” Algorithmiq CEO Sabrina Maniscalco said in the announcement.
“Our recent results provide a proof-of-concept implementation of a scalable quantum pipeline, showing how error-aware quantum algorithms can be applied to tackle one of the most fundamental challenges in drug discovery. Partnering with Quantum Circuits and leveraging their unique dual-rail qubit technology will allow us to further refine and scale these techniques, accelerating real-world impact in pharmaceutical innovation.”
Aqumen Seeker’s dual-rail qubits feature built-in error detection that enables accurate and scalable technology, allowing Algorithmiq to bypass traditional, inefficient computational methods. This next-generation system enables faster and more precise simulations, providing significant advantages in drug development timelines.
Quantum Circuits CEO Ray Smets added that Algorithmiq’s work is an important step in the quantum industry’s maturation from experimental research to commercial viability.
“Aqumen Seeker’s dual-rail qubits with built-in error detection pave the way to repeatable, consistent, and trusted quantum computing that enterprises can bet their businesses on. The possibility of certain breakthroughs in health and life sciences have been historically confined to dreams – until now,” he stated in the release.
